Human Metabolome Technologies, Inc.
Financial Summary for FY2026 Ending June
Discloses the consolidated results and outlook for the FY2026 ending June. Includes trends in revenue, operating income, ordinary income, and net income attributable to owners of the parent, along with segment composition of sales, major cost drivers, and ongoing strategy to strengthen Healthcare Solutions and develop new areas.
Key Figures
- Sales: 1,421 (Unit: million yen)
- Operating income: 209 (Unit: million yen)
- Ordinary income: 206 (Unit: million yen)
AI要約
Section heading
Overview of the consolidated results for the fiscal year ending June 2026 and the composition of segment sales. Revenue is 1,421 million yen, operating income 209 million yen, and ordinary income 206 million yen. Key factors include expansion of Healthcare Solutions, trends in manufacturing costs and selling, general and administrative expenses, and contributions by region and business. Provides breakdown of segment sales and profits, analysis of major cost drivers, and the underlying assumptions that will influence the outlook for the FY2027 results.
Section 2 heading
Future strategy and initiatives to improve profitability. Emphasis on investment in research and development for new areas, productivity gains through digitalization, new menu developments to enhance customer satisfaction, achieving profitability in Healthcare Solutions and controlling cost of goods sold to improve margins. The medium-term plan outlines growth foundations for 2024-2026, strengthening technological competitiveness, and optimizing capital allocation.
Revenue Trend
Operating Income Trend
Human Metabolomics Technologies Corporation
Company overview · Stock price · Financial data · All IR
